AnaptysBio, Inc. (NASDAQ:ANAB)’s quarterly earnings will be reported on March, 4., Faxor reports. Analysts forecast 203.33 % diference or $-0.91 from the $-0.3 EPS from 2018. After $-0.66 earnings per share was reported last quarter, analysts now see negative EPS growth of 37.88 % for AnaptysBio, Inc.. The stock increased 1.81% or $1.25 during the last trading session, hitting $70.14.Currently AnaptysBio, Inc. is downtrending after 20.28% change in last February 12, 2018. ANAB has 230,916 shares volume. The stock underperformed the S&P 500 by 20.28%.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation.The company has $1.88 billion market cap. The company??s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.Last it reported negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.
For more AnaptysBio, Inc. (NASDAQ:ANAB) news brought out briefly go to: Seekingalpha.com, Seekingalpha.com, Fool.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “AnaptysBio: Elucidating The Prospect Of The Eosinophilic Asthma Franchise – Seeking Alpha” brought out on July 26, 2018, “Aimmune up 6% premarket on publication of successful late-stage study of peanut allergy candidate AR101 – Seeking Alpha” on November 19, 2018, “AnaptysBio Sets the Stage for an Eventful Year – The Motley Fool” with a publish date: May 09, 2018, “Daily Biotech Pulse: FDA Nod For Mallinckrodt’s Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results – Benzinga” and the last “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” with publication date: January 23, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.